Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
作者： Max Schmauss , Vlado Jukić , Alberto Siracusano , Leszek Bidzan , George M. Badescu
DOI: 10.1185/03007995.2012.708327
关键词:
摘要: AbstractObjective:To extend findings from fixed-dose, double-blind, placebo-controlled clinical trials in selected patient populations by using flexibly-dosed oral paliperidone extended-release (ER) a more naturalistic setting.Methods:Adults hospitalized with an acute exacerbation of schizophrenia were prospectively treated open-label ER 3–12 mg/day for 6 weeks.Results:Overall, 294 patients treated. The primary endpoint, defined as ≥30% improvement Positive and Negative Syndrome Scale total scores baseline to was achieved 66.3% patients. percentage rated at least ‘markedly ill’ Clinical Global Impression Severity scale decreased (74.1%) endpoint (20.0%). Patient functioning, assessed the Personal Social Performance scale, improved significantly 50.0 ± 14.3 63.6 ± 14.9 (p < 0.0001). Concomitant benzodiazepines newly initiated 191 (65.0%), new...
core.ac.uk
informahealthcare.com参考文章(18)
Stefan Leucht, John P. Docherty, John M. Kane, Daniel Carpenter, The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. The Journal of Clinical Psychiatry. ,vol. 64, pp. 5- 19 ,(2003)
Herbert Y. Meltzer, William V. Bobo, Isaac F. Nuahmah, Rosanne Lane, David Hough, Michelle Kramer, Marielle Eerdekens, Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. The Journal of Clinical Psychiatry. ,vol. 69, pp. 817- 829 ,(2008) , 10.4088/JCP.V69N0515
Stephen R. Marder, Michelle Kramer, Lisa Ford, Els Eerdekens, Pilar Lim, Mariëlle Eerdekens, Adam Lowy, Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry. ,vol. 62, pp. 1363- 1370 ,(2007) , 10.1016/J.BIOPSYCH.2007.01.017
Joseph Peuskens, The management of schizophrenia: focus on extended-release quetiapine fumarate Neuropsychiatric Disease and Treatment. ,vol. 7, pp. 549- 564 ,(2011) , 10.2147/NDT.S3380
Tiemo Wessels, Dandy Grünler, Christa Bunk, Michael Specka, Markus Gastpar, Norbert Scherbaum, Eugen Davids, Changes in the Treatment of Acute Psychosis in a German Public Hospital from 1998 to 2004 Psychiatric Quarterly. ,vol. 78, pp. 91- 99 ,(2007) , 10.1007/S11126-006-9030-Y
Zafar Sharif, Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER Patient Preference and Adherence. ,vol. 2, pp. 233- 240 ,(2008) , 10.2147/PPA.S3346
Seena Fazel, Niklas Långström, Anders Hjern, Martin Grann, Paul Lichtenstein, Schizophrenia, Substance Abuse, and Violent Crime JAMA. ,vol. 301, pp. 2016- 2023 ,(2009) , 10.1001/JAMA.2009.675
Stephen R. Marder, John M. Davis, Guy Chouinard, The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis: Combined Results of the North American Trials The Journal of Clinical Psychiatry. ,vol. 58, pp. 538- 546 ,(1997) , 10.4088/JCP.V58N1205
Johannes G. Ramaekers, Antidepressants and Driver Impairment: Empirical Evidence From a Standard On-the-Road Test. The Journal of Clinical Psychiatry. ,vol. 64, pp. 20- 29 ,(2003) , 10.4088/JCP.V64N0106
Catherine Datto, Lovisa Berggren, Jitendra B. Patel, Hans Eriksson, Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clinical Therapeutics. ,vol. 31, pp. 492- 502 ,(2009) , 10.1016/J.CLINTHERA.2009.03.002